TRCT
VIR icon

Tower Research Capital (TRC)’s Vir Biotechnology VIR Stock Holding History

Tower Research Capital (TRC)’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$101K Buy
11,251
+9,179
+443% +$73.1K ﹤0.01% 2180
2025
Q4 		$12.5K Sell
2,072
-1,565
-43% -$9.32K ﹤0.01% 3473
2025
Q3 		$20.8K Sell
3,637
-4,368
-55% -$22.3K ﹤0.01% 3278
2025
Q2 		$40.3K Buy
8,005
+5,231
+189% +$28K ﹤0.01% 3154
2025
Q1 		$18K Sell
2,774
-58,617
-95% -$521K ﹤0.01% 3075
2024
Q4 		$451K Buy
61,391
+46,378
+309% +$366K 0.01% 1145
2024
Q3 		$112K Sell
15,013
-5,049
-25% -$43.9K ﹤0.01% 2140
2024
Q2 		$179K Buy
20,062
+19,081
+1,945% +$183K ﹤0.01% 2162
2024
Q1 		$9.94K Sell
981
-14,568
-94% -$148K ﹤0.01% 3774
2023
Q4 		$156K Buy
15,549
+11,278
+264% +$103K ﹤0.01% 2286
2023
Q3 		$40K Sell
4,271
-1,503
-26% -$21.4K ﹤0.01% 2737
2023
Q2 		$142K Buy
5,774
+2,073
+56% +$52.1K ﹤0.01% 1798
2023
Q1 		$86K Sell
3,701
-2,892
-44% -$74K ﹤0.01% 2009
2022
Q4 		$167K Sell
6,593
-104
-2% -$2.55K 0.01% 1429
2022
Q3 		$129K Sell
6,697
-19,975
-75% -$508K ﹤0.01% 2338
2022
Q2 		$680K Buy
26,672
+9,048
+51% +$211K 0.02% 942
2022
Q1 		$453K Buy
17,624
+1,763
+11% +$52.3K ﹤0.01% 1201
2021
Q4 		$664K Buy
15,861
+13,507
+574% +$529K 0.01% 924
2021
Q3 		$103K Sell
2,354
-1,931
-45% -$83.6K ﹤0.01% 2377
2021
Q2 		$202K Buy
4,285
+1,946
+83% +$88.5K 0.01% 1917
2021
Q1 		$120K Buy
2,339
+961
+70% +$51.8K ﹤0.01% 2453
2020
Q4 		$37K Sell
1,378
-43,664
-97% -$1.42M ﹤0.01% 3401
2020
Q3 		$1.55M Buy
45,042
+41,351
+1,120% +$1.78M 0.02% 584
2020
Q2 		$151K Buy
+3,691
New +$124K 0.01% 2064
2020
Q1 		– Sell
-1,908
Closed -$24K – 3952
2019
Q4 		$24K Buy
+1,908
New +$25.6K ﹤0.01% 1816

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Tower Research Capital (TRC)'s VIR Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Vir Biotechnology (VIR) stake by 443% in Q1 2026, buying an estimated $73.1K and bringing the position to 11,251 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #2180.

Tower Research Capital (TRC) first reported a position in VIR in Q4 2019 and has held it in 25 quarters since. The position peaked at $1.55M in Q3 2020. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Tower Research Capital (TRC) held 11,251 shares of Vir Biotechnology worth $101K as of Q1 2026.
  • Tower Research Capital (TRC) bought 9,179 Vir Biotechnology shares in Q1 2026, an estimated $73.1K.
  • Vir Biotechnology made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2180 holding.
  • Tower Research Capital (TRC) first reported a position in Vir Biotechnology in Q4 2019 and has held it in 25 quarters since.
  • Tower Research Capital (TRC)'s Vir Biotechnology position peaked at $1.55M in Q3 2020.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.